NeuroPhage Raises $9M in Series B-1


NeuroPhage Pharmaceuticals Inc., a Cambridge, Mass.-based biotech company, has raised $9 million in a Series B-1 round of financing. The round was completed by existing investors, including Merieux Developpement, Shire, and undisclosed private investors. The company has raised a total of $28.6 million since its inception in 2006.

PRESS RELEASE

NeuroPhage Pharmaceuticals, Inc. (NeuroPhage), a privately held biotechnology company focused on a novel approach for disaggregating misfolded proteins for the treatment and prevention of neurodegenerative diseases, announced today that it has secured $9.0 million in Series B-1. Dr. Michael Grundman, an Alzheimer’s disease clinical expert, President and CEO of the consulting firm Global R& D Partners, LLC, has joined the NeuroPhage team to lead the clinical development of NPT002. The round was completed by existing investors, including Merieux Developpement, Shire, and private investors. The Series B-1 financing brings the total amount of equity capital raised by NeuroPhage since its inception in 2006 to $28.6 million. The terms of the financing were not disclosed.

 

Dr. Richard Fisher, NeuroPhage’s CSO said: “The continued support of all of our investors enables us to fully exploit our recent breakthrough around the mechanism of action of NPT002.”

 

About NeuroPhage

 

NeuroPhage is a biotechnology company focusing on a unique approach for treating diseases involving protein aggregation. NeuroPhage was founded in 2007 by a Cambridge-based team along with Professor Beka Solomon, Chair for Biotechnology of Neurodegenerative Diseases at Tel Aviv University.

 

 

Connect with your peers at the 9th Annual PartnerConnect West in San Francisco on September 27–28.

Sign up to our Newsletter

Receive updates from our PE HUB Wire and Top Stories of the Week newsletters:

We will not send you spam, and we don't share your email address with 3rd parties.